Sagimet's Denifanstat: China Phase III Safety Data Isn't A Negative Signal [Seeking Alpha]
Sagimet Biosciences Inc. - Series A (SGMT)
Company Research
Source: Seeking Alpha
SGMT's Denifanstat, a first-in-class FASN inhibitor, has multiple applications—acne, MASH, and oncology—offering diversified upside if efficacy is proven across indications. Despite the sell-off, Denifanstat's China program remains on track; long-term safety data was positive and regulatory review is ongoing, with up to $122M in milestones at stake. SGMT's $125M cash position and low debt provide a 2–3 year runway, allowing key pipeline milestones to be reached without immediate financing needs. Mariya Borisova/iStock via Getty Images Thesis As you probably heard, Sagimet Biosciences ( SGMT ) shares slipped about 9% yesterday. It seems their close Chinese partner, Ascletis Pharma, released some initial late-stage trial data for Denifanstat. It's a Phase 3 open-label This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 h
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. - Series A news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences (NASDAQ:SGMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
- Sagimet Biosciences (NASDAQ:SGMT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $27.00 price target on the stock.MarketBeat
- Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe AcneGlobeNewswire
- Sagimet Biosciences (NASDAQ:SGMT) was upgraded by analysts at Barclays PLC to a "hold" rating.MarketBeat
- Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for AcnePR Newswire
SGMT
Earnings
- 11/13/25 - Beat
SGMT
Sec Filings
- 2/2/26 - Form 8-K
- 12/18/25 - Form SCHEDULE
- 12/18/25 - Form 8-K
- SGMT's page on the SEC website